Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dabigatran
Drug ID BADD_D00563
Description Dabigatran is the active form of the orally bioavailable prodrug [dabigatran etexilate].
Indications and Usage Not Available
Marketing Status approved; investigational
ATC Code B01AE07
DrugBank ID DB14726
KEGG ID D09707
MeSH ID D000069604
PubChem ID 216210
TTD Drug ID D0M7JT
NDC Product Code 51869-0030
UNII I0VM4M70GC
Synonyms Dabigatran | N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine | BIBR 1048 | Pradaxa | Dabigatran Etexilate | Etexilate, Dabigatran | Dabigatran Etexilate Mesylate | Etexilate Mesylate, Dabigatran | Mesylate, Dabigatran Etexilate
Chemical Information
Molecular Formula C25H25N7O3
CAS Registry Number 211914-51-1
SMILES CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Medical device site haemorrhage08.07.01.029; 12.02.21.013; 24.07.01.1010.000245%-
Mesenteric haemorrhage07.12.03.012; 24.07.02.0660.000245%-
Myocardial injury02.04.02.0460.000245%-
Normocytic anaemia01.03.02.0220.000489%-
Pancreatolithiasis07.18.02.0160.000245%-
Postictal paralysis17.01.04.0250.000245%-
Prosthetic cardiac valve thrombosis02.07.02.014; 08.07.07.003; 24.01.05.015; 27.01.01.0040.000245%-
Renal vein embolism20.01.07.022; 24.01.11.0060.000245%-
Right hemisphere deficit syndrome17.02.03.024; 19.21.01.0160.000367%-
Stroke in evolution17.08.01.078; 24.03.05.0210.000245%-
Subcapsular renal haematoma12.01.05.008; 20.01.02.021; 24.07.07.0060.000612%-
Subgaleal haematoma12.01.09.024; 18.04.19.001; 24.07.01.1060.000245%-
Superficial vein thrombosis24.01.02.0160.001346%-
Therapeutic product effect prolonged08.06.01.0540.000489%-
Thrombophlebitis migrans16.32.01.016; 24.01.01.0430.000245%-
Vertebrobasilar artery dissection17.08.06.006; 24.02.04.0080.000245%-
The 22th Page    First    Pre   22    Total 22 Pages